Lonza, a partner to the pharmaceutical, biotech and nutraceutical markets, has completed a planned expansion of its bioconjugation facility in Visp, Switzerland.   The expansion includes two manufacturing suites and supporting infrastructure to support an extended customer portfolio, including companies entering clinical development. The investment enhances capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand ...